Tesamorelin improves the ratio of bad cholesterol to good cholesterol by about 7% in HIV patients on medication, which is better for heart health. This finding is from the abstract summary - full study details were not available

Scientific Claim

Tesamorelin improves the cholesterol to high-density lipoprotein ratio by 7.2% in HIV patients on antiretroviral therapy with excess abdominal fat after 26 weeks of treatment compared to placebo.

Original Statement

“cholesterol to high-density lipoprotein ratio (-0.18 +/- 1.00 vs. 0.18 +/- 0.94, P < 0.001; treatment effect, -7.2%) vs. placebo.”

From study:Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.

Evidence Quality Assessment

Claim Status

overstated

Study Design Support

Design supports claim

Appropriate Language Strength

probability

Can suggest probability/likelihood

Assessment Explanation

Based on abstract only - full methodology not available to verify; blinding status unknown, so definitive language is inappropriate.

More Accurate Statement

“Tesamorelin is likely to improve the cholesterol to high-density lipoprotein ratio by 7.2% in HIV patients on antiretroviral therapy with excess abdominal fat after 26 weeks of treatment compared to placebo.”

Evidence from Studies

Supporting (1)

Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.

Randomized Controlled Trial

Human

2010 Sep

Contradicting (0)

No contradicting evidence found

Source Study

Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.

Score: 62

DOI: 10.1210/jc.2010-0490

Similar Assertions

HIV patients on medication who keep taking tesamorelin for a year continue to have less belly fat, lower triglycerides, and better cholesterol levels compared to when they started. This finding is from the abstract summary - full study details were not available

91%

Tesamorelin helps lower triglycerides, a type of fat in the blood, by about 12% in HIV patients on medication compared to those not taking it. This finding is from the abstract summary - full study details were not available

88%

A hormone treatment called tesamorelin lowers liver fat by 2.9% more than a placebo in people with HIV who have excess abdominal fat after six months of treatment.

83%

A drug called tesamorelin helps HIV patients with belly fat buildup lose about 11% of their dangerous internal belly fat in six months, while those on a dummy pill lose almost none.

82%

A drug called tesamorelin helps reduce belly fat deep inside the abdomen for people with HIV who are on medication, making their belly fat decrease by about 15% compared to those not taking the drug. This finding is from the abstract summary - full study details were not available

82%